Ctd Holdings Inc (CTDH) 0.6000 $CTDH
FDA Accepts CTD Holdings' Drug Master File for Second-Generation Orphan Drug
Marketwire Canada - Tue Jan 27, 5:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distributes and manufactures cyclodextrin-based products, today announced that the U.S. Food and Drug Administration accepted CTD's Type II Drug Master File No. 28889 covering its second-generation TrappsolA® Cycloa"c orphan drug product.
N. Scott Fine Named Board Chairman of Global Virus Network
Marketwired - Thu Jan 08, 6:01AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced that board chairman N. Scott Fine has been elected Chairman of the Board of Directors of Global Virus Network (GVN), a non-profit organization whose mission is to combat current viral threats and emerging pandemic threats worldwide.
CTD Holdings appoints Dr Sharon H. Hrynkow to SAB
M2 - Tue Nov 11, 6:51AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) disclosed on Monday the addition of Dr Sharon H. Hrynkow, PhD to its new Scientific Advisory Board (SAB).
CTD Holdings Names Dr. Sharon H. Hrynkow to Scientific Advisory Board
Marketwired - Mon Nov 10, 6:01AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of Sharon H. Hrynkow, Ph.D., to the company's new Scientific Advisory Board. Dr. Hrynkow, who is the board's inaugural member and a developmental neuroscientist by training, has extensive experience leading global health programs and policy efforts at federal and non-profit agencies such as the National Institutes of Health (NIH), the U.S. State Department, and the Global Virus Network.
CTD Holdings Names New Board Chairman
Marketwire - Wed Oct 01, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of N. Scott Fine as Chairman of the Board of Directors. Mr. Fine, who recently became Vice Chairman and Lead Director, is a seasoned finance executive with more than 35 years of experience in helping public companies to realize their full potential.
CTD Holdings Reports Progress in Orphan Drug Development and Acquires Equity Capital in Second Quarter
Marketwire - Fri Aug 15, 7:04AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies based on cyclodextrin chemistry, today reported continued progress on its orphan drug development in its second-quarter filing with the Securities and Exchange Commission. Validation of the manufacturing process for the Trappsol® Cyclo(TM) product is proceeding as expected, and the Company plans to file its Drug Master File with the Food and Drug Administration in the third quarter. In the second quarter and July, the Company closed on two rounds of private equity totaling $2.725 million.
CTD Holdings raises USD1.725m from private placement in preparation for clinical trials
M2 - Wed Jul 23, 7:12AM CDT
Cyclodextrins supplier CTD Holdings (Other OTC:CTDH) reported on Tuesday the issuance of 1,725,000 shares of common stock in a private placement with a group of qualified private investors led by Novit, an investment arm of US Pharmacia.
CTD Holdings Closes $1.725 Million Private Placement
PRWeb - Tue Jul 22, 11:05AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm of U.S. Pharmacia.
CTD Holdings announces change in executive roles
M2 - Thu Jul 10, 5:07AM CDT
Cyclodextrin products company CTD Holdings (Other OTC:CTDH) stated on Wednesday that Dr. Jeffrey Tate has been promoted to the chief executive officer role.
CTD Holdings Names New Chief Executive
PRWeb - Wed Jul 09, 11:03AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer, following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of President and CEO of CTD Holdings, Inc.; Mr. Strattan will become Executive Chairman. Dr. Tate has been President of CTD for 3 years and is a seasoned executive with more than 30 years of experience in both academic and industrial biotechnology. Mr. Strattan is the founder of the CTD Holdings Family of Companies and took the company public in 1994.
FDA Accepts CTD Holdings' Drug Master File for Second-Generation Orphan Drug
Marketwire Canada - Tue Jan 27, 5:00AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distributes and manufactures cyclodextrin-based products, today announced that the U.S. Food and Drug Administration accepted CTD's Type II Drug Master File No. 28889 covering its second-generation TrappsolA® Cycloa"c orphan drug product.
N. Scott Fine Named Board Chairman of Global Virus Network
Marketwired - Thu Jan 08, 6:01AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced that board chairman N. Scott Fine has been elected Chairman of the Board of Directors of Global Virus Network (GVN), a non-profit organization whose mission is to combat current viral threats and emerging pandemic threats worldwide.
CTD Holdings appoints Dr Sharon H. Hrynkow to SAB
M2 - Tue Nov 11, 6:51AM CST
Biotechnology company CTD Holdings (Other OTC:CTDH) disclosed on Monday the addition of Dr Sharon H. Hrynkow, PhD to its new Scientific Advisory Board (SAB).
CTD Holdings Names Dr. Sharon H. Hrynkow to Scientific Advisory Board
Marketwired - Mon Nov 10, 6:01AM CST
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of Sharon H. Hrynkow, Ph.D., to the company's new Scientific Advisory Board. Dr. Hrynkow, who is the board's inaugural member and a developmental neuroscientist by training, has extensive experience leading global health programs and policy efforts at federal and non-profit agencies such as the National Institutes of Health (NIH), the U.S. State Department, and the Global Virus Network.
CTD Holdings Names New Board Chairman
Marketwire - Wed Oct 01, 6:00AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo(TM), today announced the appointment of N. Scott Fine as Chairman of the Board of Directors. Mr. Fine, who recently became Vice Chairman and Lead Director, is a seasoned finance executive with more than 35 years of experience in helping public companies to realize their full potential.
CTD Holdings Reports Progress in Orphan Drug Development and Acquires Equity Capital in Second Quarter
Marketwire - Fri Aug 15, 7:04AM CDT
CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies based on cyclodextrin chemistry, today reported continued progress on its orphan drug development in its second-quarter filing with the Securities and Exchange Commission. Validation of the manufacturing process for the Trappsol® Cyclo(TM) product is proceeding as expected, and the Company plans to file its Drug Master File with the Food and Drug Administration in the third quarter. In the second quarter and July, the Company closed on two rounds of private equity totaling $2.725 million.
CTD Holdings raises USD1.725m from private placement in preparation for clinical trials
M2 - Wed Jul 23, 7:12AM CDT
Cyclodextrins supplier CTD Holdings (Other OTC:CTDH) reported on Tuesday the issuance of 1,725,000 shares of common stock in a private placement with a group of qualified private investors led by Novit, an investment arm of US Pharmacia.
CTD Holdings Closes $1.725 Million Private Placement
PRWeb - Tue Jul 22, 11:05AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm of U.S. Pharmacia.
CTD Holdings announces change in executive roles
M2 - Thu Jul 10, 5:07AM CDT
Cyclodextrin products company CTD Holdings (Other OTC:CTDH) stated on Wednesday that Dr. Jeffrey Tate has been promoted to the chief executive officer role.
CTD Holdings Names New Chief Executive
PRWeb - Wed Jul 09, 11:03AM CDT
CTD Holdings, Inc. (OTCQB:CTDH), a distributor and manufacturer of cyclodextrin products including the orphan drug designated Trappsol(R) Cyclo(TM), today announced the promotion of Dr. Jeffrey Tate to Chief Executive Officer, following the retirement of C.E. Rick Strattan. Dr. Tate will hold the titles of President and CEO of CTD Holdings, Inc.; Mr. Strattan will become Executive Chairman. Dr. Tate has been President of CTD for 3 years and is a seasoned executive with more than 30 years of experience in both academic and industrial biotechnology. Mr. Strattan is the founder of the CTD Holdings Family of Companies and took the company public in 1994.
